AKT1 and breast cancer: In further support of this hypothesis, inhibition of EGFR effectively abolished the adverse AKT activation caused by MEK inhibition alone; and combined MEK-PI3K inhibition synergistically suppressed growth in 4 of the 11 BC cell lines tested[27].